H
Hua You
Researcher at Guangzhou Medical University
Publications - 12
Citations - 320
Hua You is an academic researcher from Guangzhou Medical University. The author has contributed to research in topics: Immune checkpoint & Immune system. The author has an hindex of 7, co-authored 12 publications receiving 143 citations. Previous affiliations of Hua You include Duke University.
Papers
More filters
Journal ArticleDOI
Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL
Ziju Y. Xu-Monette,Min Xiao,Qingyan Au,Raghav Padmanabhan,Bing Xu,Nicholas Hoe,Sandra Rodriguez-Perales,Raúl Torres-Ruiz,Ganiraju C. Manyam,Carlo Visco,Yi Miao,Xiaohong Tan,Hongwei Zhang,Alexandar Tzankov,Jing Wang,Karen Dybkær,Wayne Tam,Hua You,Govind Bhagat,Eric D. Hsi,Maurilio Ponzoni,Andrés J.M. Ferreri,Michael Boe Møller,Miguel A. Piris,J. Han van Krieken,Jane N. Winter,Jason R. Westin,Lan V. Pham,L. Jeffrey Medeiros,George Z. Rassidakis,Yong Li,Gordon J. Freeman,Ken H. Young,Ken H. Young +33 more
TL;DR: TheDLBCL immune landscape is comprehensively characterized, the differential roles of various checkpoint components in rituximab–CHOP resistance in DLBCL patients are deciphered, and targets for PD-1/PD-L1 blockade and combination immunotherapies are suggested.
Journal ArticleDOI
The Combination of Immune Checkpoint Blockade and Angiogenesis Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer.
TL;DR: In this article, the authors outline the current understanding of the mechanisms of vascular endothelial growth factor/vascular endothelium growth factor receptor (VEGF/VEGFR) signaling in tumor immune escape and progression, and summarize the preclinical studies and current clinical data of the combination of immunotherapy with anti-angiogenic drugs in the treatment of advanced NSCLC.
Journal ArticleDOI
Immune Microenvironment of Brain Metastases—Are Microglia and Other Brain Macrophages Little Helpers?
TL;DR: Microglia and non-parenchymal brain macrophages are involved in multiple stages of a metastatic disease and, unlike tumor cells, are genetically stable and predictable, which makes them an attractive target for anticancer therapies.
Journal ArticleDOI
PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program.
Ling Li,Ruifang Sun,Yi Miao,Thai Tran,Lisa Adams,Nathan Roscoe,Bing Xu,Ganiraju C. Manyam,Xiaohong Tan,Hongwei Zhang,Min Xiao,Alexandar Tzankov,Carlo Visco,Karen Dybkær,Govind Bhagat,Wayne Tam,Eric D Hsi,J. Han van Krieken,Hua You,Jooryung Huh,Maurilio Ponzoni,Andrés J M Ferreri,Michael Boe Møller,Miguel A. Piris,Mingzhi Zhang,Jane N. Winter,L. Jeffrey Medeiros,George Z. Rassidakis,Christine Vaupel,Yong Li,Naveen Dakappagari,Zijun Y. Xu-Monette,Ken H. Young,Ken H. Young +33 more
TL;DR: The results suggest the benefit of PD-1/PD-L1 blockade therapies only in patients with sufficient T-cell infiltration, and the potential of immunofluorescent assays and Automated Quantitative Analysis in the clinical assessment of PD/L1 expression and interaction.
Journal ArticleDOI
RUNX1 contributes to the mesenchymal subtype of glioblastoma in a TGFβ pathway-dependent manner.
Kai Zhao,Kai Zhao,Xiaoteng Cui,Qixue Wang,Chuan Fang,Yanli Tan,Yunfei Wang,Kaikai Yi,Chao Yang,Hua You,Rui Shang,Jiachong Wang,Chunsheng Kang +12 more
TL;DR: It is found and verified that BCL3 and MGP are transcriptionally activated by p-SMAD3 /RUNX1, while MXI1 is transcriptionally suppressed by the RUNX1/SUV39H1-H3K9me3 axis.